test

Nathan Fischel

@Dafna Capital Management Llc

Latest period2024 - Q3ReportedManaged Assets$423.312MTotal holdings84
Assets growth rate1.14%Assets growth rate (2-Q avg)-1.79%Continuous growth in asset value1 quarters

Portfolio positions

This chart displays the top 10 holdings in Dafna Capital Management Llc's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 84 positions.

Assets under management

The assets under management (AUM) of Dafna Capital Management Llc over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 423.312M in assets, with a quarterly growth rate of 1.14% and a 2-quarter average growth rate of -1.79%. The portfolio is managed by Nathan Fischel, and others.

Portfolio holdings

CurrentNew PositionIncreasedDecreasedExited
InvestmentPortfolio %Reported Value
XBISpdr S&p Biotech Etf
Recent Activity
Decreased -9.77%
9.38%
$39.669M
401,505 shares@ $98.8 avg price
SNDXSyndax Pharmaceuticals Inc
Recent Activity
Decreased -19.84%
2.4%
$10.139M
526,702 shares@ $19.26 avg price
BHVNBiohaven Ltd
Recent Activity
Decreased -14.44%
2.21%
$9.351M
187,130 shares@ $49.97 avg price
KALVKalvista Pharmaceuticals Inc
Recent Activity
Decreased -10.32%
1.98%
$8.38M
723,678 shares@ $11.58 avg price
NBIXNeurocrine Biosciences Inc
Recent Activity
Decreased -2.79%
1.9%
$8.021M
69,615 shares@ $115.22 avg price
KURAKura Oncology Inc
Recent Activity
Decreased -3.57%
1.89%
$7.98M
408,368 shares@ $19.55 avg price
VKTXViking Therapeutics Inc
Recent Activity
Decreased -33.57%
1.88%
$7.953M
125,616 shares@ $63.32 avg price
EWTXEdgewise Therapeutics Inc
Recent Activity
Decreased -21.46%
1.44%
$6.083M
227,906 shares@ $26.69 avg price
URGNUrogen Pharma Ltd
Recent Activity
Decreased -2.15%
1.38%
$5.828M
458,915 shares@ $12.71 avg price
BCRXBiocryst Pharmaceuticals Inc
Recent Activity
Decreased -5.32%
1.2%
$5.069M
667,000 shares@ $7.6 avg price